Liquidia Corp

LQDA

Market cap $3B

Liquidia Corporation (LQDA) Q4 2025 Earnings Call Transcript

Liquidia Corporation (LQDA) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to a loss of $0.46 per share a year ago.

MORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the full year ended December 31, 2025. The company will also host a webcast at 8:30 a.m. ET on March 5, 2026, to discuss its financial results and provide a corporate update.

Sold 180,000 shares of Liquidia; estimated transaction value ~$5.12 million based on quarterly average price Quarter-end Liquidia position value rose by $25.52 million, reflecting both trading and stock price movement Sale equaled 0.68% of fund's 13F assets under management Post-trade holding: 2,435,000 shares, valued at $84.98 million Liquidia now represents 11.21% of fund AUM, which places it outside the fund's top five holdings

Liquidia has rapidly captured 16% market share in pulmonary hypertension since launching Yutrepia in June 2025, with momentum likely to continue. LQDA's superior product profile is driving patient switches from United Therapeutics, supporting robust revenue and cash flow growth projections. Assuming 50% market share and 20% market growth, LQDA could be trading at under 7x cash flow by year-end 2026, implying material undervaluation.

MORRISVILLE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that it will report its full year 2025 financial results on Thursday, March 5, 2026.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Liquidia Corporation (LQDA). But which of these two stocks offers value investors a better bang for their buck right now?

Does Liquidia Corporation (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Liquidia Corporation (LQDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The biotech posted preliminary sales results for Yutrepia. This is its latest commercialized product, approved by the FDA in May 2025.